Financing ·
PDS Biotechnology Corporation entered into a First Amendment to Promissory Note with YA II PN, Ltd., modifying the…
PDSBPDS Biotechnology Corp
PDS Biotechnology Corporation entered into a First Amendment to Promissory Note with YA II PN, Ltd., modifying the terms of a $6,000,000 promissory note originally issued on June 15, 2026. The amendment requires weekly remittance notices for net proceeds from at-the-market offerings and mandates that 100% of net cash proceeds from any other equity or equity-linked financing be applied as a mandatory deemed redemption to the holder within five business days. Additionally, the cure period for Nasdaq listing deficiencies was extended from 75 to 180 days. The amendment becomes effective upon execution and payment of the installment due on September 14, 2026. PDS Biotechnology Corporation operates in the biotechnology industry, focusing on developing immunotherapies.